JPRN-jRCT2080221666未知2 期
Exploratory study of OPC-12759 Ophthalmic Suspension for patients with keratoconjunctival epithelial disorder
Otsuka Pharmaceuticals Co., Ltd.0 个研究点目标入组 100 人开始时间: 2011年12月5日最近更新:
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Diagnosis of superficial punctate keratopathy or corneal erosion
- •2. Fluorescein corneal staining score of 3 or higher
排除标准
- •1. Active ocular infection
- •2. Vernal keratoconjunctivitis
- •3. Recurrent corneal erosion
- •4. Physical irritation of eyelashes or relaxed bulbar conjunctiva to cornea or conjunctiva
- •5. Subjects who cannot discontinue or anticipate use of eye drops except for limited concomitant ones during the study. Soft-santear is allowed during the screening period.
- •6. Anticipated use of contact lens during the study.
- •7. Insertion of punctal plug or fall out of punctal plug within 3 months
- •8. Subjects who are judged by the investigator to be ineligible for the study because of a past or concurrent systemic disease.
- •9. Receipt of any investigational product within 4 months
研究者
相似试验
未知
3 期
Confirmatory Study of OPC-12759 Ophthalmic SuspensioJPRN-jRCT2080220723Otsuka Pharmaceuticals Co., Ltd.180
已完成
2 期
Exploratory Study of OPC-12759 Ophthalmic SuspensionKeratoconjunctival Epithelial DisorderNCT01493180Otsuka Pharmaceutical Co., Ltd.102
未知
2 期
ate phase 2 study of OPC-12759 ophthalmic suspensioDry eyeJPRN-jRCT2080220394Otsuka Pharmaceutical Co., Ltd.
未知
2 期
Dose-response study of OPC-12759 ophthalmic suspensioDry eyeJPRN-jRCT2080220040Otsuka Pharmaceutical Co., Ltd.
已完成
3 期
Confirmatory Study of OPC-12759 Ophthalmic SuspensionDry Eye SyndromesNCT00885079Otsuka Pharmaceutical Co., Ltd.188